Skip to main content

Table 3 Auditory evoked potentials in the study groups

From: Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols

 

NY

pBFM

BFM95

Control

P value

Prolonged latency of wave I

3 (8.6)

4 (8.5)

6 (7.1)

–

0.872

Prolonged latency of wave III

5 (14.3)

10 (21.3)

21 (24.7)

–

0.406

Prolonged latency of wave V

5 (14.3)

9 (19.2)

14 (16.5)

–

0.658

Prolonged interwave I-III latency

13 (37.1)

13 (27.7)

29 (34.1)

–

0.795

Prolonged interwave III-V latency

10 (28.6)

16 (34.0)

28 (32.9)

–

0.610

Prolonged interwave I-V latency

17 (48.6)

17 (36.2)

44 (51.8)

–

0.307

Latency of wave I

1.52

1.75

1.64

1.91

0.001*

Latency of wave III

3.82

3.96

3.87

3.98

0.615

Latency of wave V

6.14

6.27

6.14

6.16

0.990

Interwave I-III latency

2.21

2.19

2.26

2.04

0.081

Interwave III-V latency

2.33

2.33

2.34

2.20

0.562

Interwave I-V latency

4.58

4.52

4.59

4.24

0.035

  1. * NY vs control P = 0.002, BFM95 vs control P = 0.011
  2. Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol